Forest and Almirall to Present Data from Phase III Studies of Aclidinium Bromide in Chronic Obstructive Pulmonary Disease

Forest Laboratories, Inc.

and Almirall, S.A. today announced that they are presenting additional data from ATTAIN, a pivotal Phase III study comparing the efficacy and safety of inhaled aclidinium bromide 200μg and 400μg twice daily (

) versus placebo in patients with moderate to severe COPD, at ATS 2011, the annual International Conference of the American Thoracic Society taking place in Denver May 13-18, 2011. Positive top-line results from this six-month double-blind placebo-controlled study were first reported in January 2011. Additional detail from the ATTAIN study, which was accepted as a late-breaker, will be presented in poster format on Sunday, May 15th (8:15 am - 4:30 pm, Session A45, D100, PW Jones).